BrainCool AB (SE:BRAIN)
:BRAIN
Want to see SE:BRAIN full AI Analyst Report?
Top Page
BrainCool AB
(BRAIN)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr0.87
▲(49.48% Upside)
Action:ReiteratedDate:04/22/26
The score is held back primarily by weak fundamentals—persistent losses, negative gross profit in 2025, and continued cash burn—despite a debt-free balance sheet. Technicals are supportive with the stock trading above major moving averages and a positive MACD, but overbought indicators (RSI/Stoch) add near-term risk. Valuation is also constrained by negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero reported debt across 2022–2025 gives BrainCool durable financial flexibility. Without interest burden the company can prioritize R&D, commercialization and clinical rollout funding from available equity and cash, reducing near-term default risk and enabling strategic choices.
Negative Factors
Persistent negative free cash flow
Sustained negative operating and free cash flow indicates real cash burn rather than accounting items. Continued outflows will force external financing or equity raises, constraining strategic options, increasing dilution risk and limiting ability to self-fund commercialization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt across 2022–2025 gives BrainCool durable financial flexibility. Without interest burden the company can prioritize R&D, commercialization and clinical rollout funding from available equity and cash, reducing near-term default risk and enabling strategic choices.
Read all positive factors
BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr319.85M
Dividend YieldN/A
Average Volume (3M)201.46K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth-9.38%
EPS Growth19.51%
CountrySE
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.00
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)kr72.00M
BrainCool AB Business Overview & Revenue Model
Company Description
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatmen...
How the Company Makes Money
BrainCool makes money primarily by selling and/or leasing its temperature-management medical device systems and by generating recurring revenue from associated single-use or consumable components used with those systems (where applicable). Revenue...
BrainCool AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.21M | 39.96M | 23.23M | 17.59M | 9.26M |
| Gross Profit | -40.88M | 13.13M | 12.12M | -46.16M | -48.93M |
| EBITDA | -29.99M | -34.06M | -49.86M | -35.07M | -32.16M |
| Net Income | -37.05M | -44.04M | -61.28M | -45.61M | -38.75M |
Balance Sheet | |||||
| Total Assets | 192.38M | 162.04M | 133.28M | 133.67M | 99.35M |
| Cash, Cash Equivalents and Short-Term Investments | 39.57M | 31.40M | 25.06M | 41.21M | 13.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 35.00M |
| Total Liabilities | 16.58M | 16.11M | 21.54M | 17.44M | 54.12M |
| Stockholders Equity | 175.80M | 145.93M | 111.74M | 116.23M | 45.23M |
Cash Flow | |||||
| Free Cash Flow | -56.49M | -70.20M | -67.23M | -53.67M | -35.06M |
| Operating Cash Flow | -52.68M | -62.64M | -61.16M | -46.27M | -24.25M |
| Investing Cash Flow | -6.54M | -7.57M | -6.17M | -7.59M | -10.82M |
| Financing Cash Flow | 67.33M | 76.80M | 50.93M | 81.28M | 36.39M |
BrainCool AB Technical Analysis
Positive
0.58
Price Trends
0.56
Positive
0.55
Positive
0.79
Negative
Market Momentum
0.06
Negative
72.81
Negative
93.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.56, and below the 200-day MA of 0.79, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 72.81 is Negative, neither overbought nor oversold. The STOCH value of 93.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BRAIN.
BrainCool AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr365.63M | -11.61 | -27.25% | ― | -3.87% | -81.16% | |
55 Neutral | kr847.55M | 103.06 | 6.93% | ― | -5.76% | -81.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr630.79M | -25.75 | -2.52% | ― | -10.66% | 73.69% | |
49 Neutral | kr1.02B | -61.68 | -4.42% | ― | 4.66% | 27.83% | |
48 Neutral | kr319.85M | -4.05 | -27.22% | ― | -9.38% | 19.51% | |
48 Neutral | kr312.28M | -6.28 | -104.38% | ― | 18.65% | 41.27% |
* Healthcare Sector Average
SE:BRAIN
BrainCool AB
0.81
-0.98
-54.82%
SE:BACTI.B
Bactiguard Holding AB
18.00
-13.70
-43.22%
SE:CRAD.B
C-Rad AB Class B
25.10
-4.90
-16.33%
SE:ACARIX
Acarix AB
0.28
0.07
31.13%
SE:SEDANA
Sedana Medical AB
10.22
0.00
0.00%
SE:MNTC
Mentice AB
13.00
-7.47
-36.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.